Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ptc Therapeutics (NQ: PTCT )

42.89 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 42.89
Bid (Size) 17.16 (2)
Ask (Size) 68.19 (1)
Prev. Close 42.89
Today's Range 42.89 - 42.89
52wk Range 20.75 - 46.98
Shares Outstanding 77,125,143
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC deficiency treatment. 
Via Benzinga
Exposures Product Safety
Earnings Preview For PTC Therapeutics
Via Benzinga

Performance

YTD
+52.96%
+52.96%
1 Month
+9.08%
+9.08%
3 Month
+28.30%
+28.30%
6 Month
+15.51%
+15.51%
1 Year
+98.38%
+98.38%

More News

Read More
3 Top Stocks That Could Still Rocket Higher in 2024
Via The Motley Fool
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
Via Investor's Business Daily
PTCT Stock Earnings: PTC Therapeutics Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Recap: PTC Therapeutics Q4 Earnings
Via Benzinga
Earnings Scheduled For February 29, 2024
Via Benzinga
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again
Via Investor's Business Daily
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Via Benzinga
Earnings Preview: PTC Therapeutics
Via Benzinga
PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder
Via Benzinga
Exposures Product Safety
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
Via InvestorPlace
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
European Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual Guidance
Via Benzinga
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
Via Investor's Business Daily
PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
Via The Motley Fool
PTC Therapeutics Flashes A Bearish Sign After European Officials Reject DMD Drug
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.